================================================================================
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2001

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                           Commission File No. 0-20260
                           Commission File No. 1-11440


                            INTEGRAMED AMERICA, INC.
             (Exact name of Registrant as specified in its charter)


          Delaware                                    06-1150326
(State or other jurisdiction of         (I.R.S. employer identification no.)
 incorporation or organization)


     One Manhattanville Road                                10577
        Purchase, New York
(Address of principal executive offices)                 (Zip code)



                                 (914) 253-8000
              (Registrant's telephone number, including area code)

         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.


                           Yes [X]            No [  ]



         The aggregate number of shares of the Registrant's Common Stock, $.01
par value, outstanding on July 31, 2001 was 2,993,486.

================================================================================

<PAGE>


                            INTEGRAMED AMERICA, INC.
                                    FORM 10-Q

                                TABLE OF CONTENTS


                                                                           PAGE
                                                                           ----
PART I  -    FINANCIAL INFORMATION

    Item 1.  Financial Statements

                Consolidated Balance Sheets at June 30, 2001 (unaudited)
                  and December 31, 2000....................................... 3

                Consolidated Statements of Operations for the three and
                  six-month periods ended June 30, 2001 and 2000 (unaudited).. 4

                Consolidated Statements of Cash Flows for the six-month
                  periods ended June 30, 2001 and 2000 (unaudited)............ 5

                Notes to Consolidated Financial Statements (unaudited)...... 6-8

    Item 2.  Management's Discussion and Analysis of Financial Condition
              and Results of Operations.................................... 9-12

    Item 3.  Quantitative and Qualitative Disclosures About Market Risk.......12


PART II -    OTHER INFORMATION

    Item 1.  Legal Proceedings................................................13

    Item 2.  Changes in Securities............................................13

    Item 3.  Defaults upon Senior Securities..................................13

    Item 4.  Submission of Matters to a Vote of Security Holders..............13

    Item 5.  Other Information................................................13

    Item 6.  Exhibits and Reports on Form 8-K.................................13


SIGNATURES            ........................................................14


                                      -2-
<PAGE>


PART I -- FINANCIAL INFORMATION

    Item 1.      Consolidated Financial Statements
<TABLE>

                            INTEGRAMED AMERICA, INC.
                           CONSOLIDATED BALANCE SHEETS
              (all dollars in thousands, except per share amounts)

                                     ASSETS
<CAPTION>
                                                                                                 June 30      December 31,
                                                                                                 -------      ------------
                                                                                                   2001           2000
                                                                                                 -------      ------------
                                                                                               (unaudited)
Current assets:
<S>                                                                                             <C>             <C>
  Cash and cash equivalents ..................................................................  $  5,145        $  5,306
  Patient accounts receivable, less allowance for doubtful accounts of $1,968 and $1,457
    in 2001 and 2000, respectively ...........................................................    11,602          10,991
  Business Service fees receivable ...........................................................      --               237
  Prepaids and other current assets ..........................................................     1,041           1,283
                                                                                                --------        --------
      Total current assets ...................................................................    17,788          17,817
  Fixed assets, net ..........................................................................     5,840           5,337
  Intangible assets, net .....................................................................    17,571          17,774
  Other assets ...............................................................................       469             367
                                                                                                --------        --------
      Total assets ...........................................................................  $ 41,668        $ 41,295
                                                                                                ========        ========

                      LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
  Accounts payable ...........................................................................  $  1,776        $  1,700
  Accrued liabilities ........................................................................     4,593           5,059
  Due to Medical Practices ...................................................................     3,610           2,450
  Current portion of long-term notes payable and other obligations ...........................     1,140           1,135
  Patient deposits ...........................................................................     4,127           2,530
                                                                                                --------        --------
      Total current liabilities ..............................................................    15,246          12,874
                                                                                                --------        --------
Long-term notes payable and other obligations ................................................     1,862           2,434
                                                                                                --------        --------
Shareholders' equity:
  Preferred Stock, $1.00 par value - 3,165,644 shares authorized in 2001 and
    2000, 2,500,000 undesignated; 665,644 shares designated as Series A
    Cumulative Convertible of which 165,644 shares were issued and outstanding
    in 2001 and
    2000, respectively .......................................................................       166             166
  Common Stock, $.01 par value -  50,000,000 shares authorized in 2001 and 2000;
    and 5,473,571 and 5,413,571 shares issued in 2001 and 2000, respectively .................        55              54
  Capital in excess of par ...................................................................    54,085          54,149
  Accumulated deficit ........................................................................   (22,548)        (23,313)
 Restricted Stock Grants .....................................................................      (100)           --
  Treasury Stock, at cost - 2,480,085 and 1,600,013 shares in 2001 and 2000, respectively ....    (7,098)         (5,069)
                                                                                                --------        --------
      Total shareholders' equity .............................................................    24,560          25,987
                                                                                                --------        --------
      Total liabilities and shareholders' equity .............................................  $ 41,668        $ 41,295
                                                                                                ========        ========

        See accompanying notes to the consolidated financial statements.

</TABLE>
                                      -3-


<PAGE>

<TABLE>

                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
              (all amounts in thousands, except per share amounts)

<CAPTION>

                                                                                   For the                    For the
                                                                             three-month period          six-month period
                                                                               ended June 30,              ended June 30,
                                                                            --------------------        -------------------
                                                                              2001         2000          2001         2000
                                                                            -------      -------        -------     -------
                                                                                (unaudited)                 (unaudited)

<S>                                                                        <C>          <C>             <C>         <C>
Revenues, net ......................................................       $ 18,287     $ 13,527        $ 34,778    $ 27,135

Cost of services incurred:
   Employee compensation and related expenses ......................          7,433        5,370          13,633      10,467
   Direct materials ................................................          3,958        2,680           7,776       5,161
   Occupancy costs .................................................            873          847           1,872       1,660
   Depreciation ....................................................            300          345             574         679
   Other expenses ..................................................          3,116        2,206           5,969       5,119
                                                                           --------     --------        --------    --------
     Total cost of services incurred ...............................         15,680       11,448          29,824      23,086
                                                                           --------     --------        --------    --------

Contribution .......................................................          2,607        2,079           4,954       4,049

General and administrative expenses ................................          1,880        1,390           3,569       2,739
Amortization of intangible assets ..................................            225          214             441         434
Interest income ....................................................            (44)         (35)            (98)        (85)
Interest expense ...................................................             77          103             163         219
                                                                           --------     --------        --------    --------
   Total other expenses ............................................          2,138        1,672           4,075       3,307
                                                                           --------     --------        --------    --------

Income before income taxes .........................................            469          407             879         742
Provision for income taxes .........................................             63           39             114          84
                                                                           --------     --------        --------    --------

Net income .........................................................       $    406     $    368        $    765    $    658
Less: Dividends paid and/or accrued on Preferred Stock .............             33           33              66          66
                                                                           --------     --------        --------    --------
Net income applicable to Common Stock ..............................       $    373     $    335        $    699    $    592
                                                                           ========     ========        ========    ========

Basic and diluted earnings per share of Common Stock ...............       $   0.12     $   0.08        $   0.22    $   0.14
                                                                           ========     ========        ========    ========

Weighted average shares - basic ....................................          2,993        4,163           3,109       4,270
                                                                           ========     ========        ========    ========
Weighted average shares - diluted ..................................          3,105        4,226           3,150       4,334
                                                                           ========     ========        ========    ========

</TABLE>

        See accompanying notes to the consolidated financial statements.

                                      -4-

<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (all amounts in thousands)

<CAPTION>
                                                                                                  For the
                                                                                             six-month period
                                                                                              ended June 30,
                                                                                             ----------------
                                                                                              2001      2000
                                                                                             ------    ------
                                                                                                (unaudited)
Cash flows from operating activities:
<S>                                                                                         <C>        <C>
   Net income ............................................................................  $   765    $   658
   Adjustments to reconcile net income to net cash provided by operating activities:
   Depreciation and amortization .........................................................    1,229      1,349
   Change in assets and liabilities -- Decrease (increase) in assets:
        Patient accounts receivable ......................................................     (611)     1,030
        Business Services fees receivable ................................................      237        515
        Other current assets .............................................................      367        (22)
        Other assets .....................................................................       33         32
     (Decrease) increase in liabilities:
         Accounts payable ................................................................       76        683
         Accrued liabilities .............................................................     (826)        19
         Due to Medical Practices ........................................................    1,160        (37)
         Patient deposits ................................................................    1,597       (278)
                                                                                            -------    -------
Net cash provided by operating activities ................................................    4,027      3,949
                                                                                            -------    -------

Cash flows used in investing activities:
     Purchase of fixed assets and leasehold improvements .................................   (1,291)      (588)
     Payment for exclusive business service rights .......................................     (238)      (476)
     Proceeds from sale of fixed assets and leasehold improvements .......................     --           10
                                                                                            -------    -------
Net cash used in investing activities ....................................................   (1,529)    (1,054)
                                                                                            -------    -------

Cash flows used in financing activities:
     Principal repayments on debt ........................................................     (500)    (1,060)
     Principal repayments under capital lease obligations ................................      (67)       (66)
     Repurchase of Common Stock ..........................................................   (2,029)    (1,821)
     Proceeds from exercise of Common Stock warrants .....................................        3       --
     Dividends paid on Convertible Preferred Stock .......................................      (66)       (66)
                                                                                            -------    -------
Net cash used in financing activities ....................................................   (2,659)    (3,013)
                                                                                            -------    -------

Net decrease in cash .....................................................................     (161)      (118)
Cash at beginning of period ..............................................................    5,306      3,650
                                                                                            -------    -------
Cash at end of period ....................................................................  $ 5,145    $ 3,532
                                                                                            =======    =======

</TABLE>

        See accompanying notes to the consolidated financial statements.

                                      -5-

<PAGE>


                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1 -- INTERIM RESULTS:

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance with the instructions to Form 10-Q and,  accordingly,  do
not include all of the information and footnotes  required by generally accepted
accounting  principles  for  complete  financial  statements.  In the opinion of
management,  the accompanying unaudited interim financial statements contain all
adjustments  (consisting only of normal recurring accruals) necessary to present
fairly the  financial  position at June 30, 2001,  and the results of operations
and cash flows for the  interim  period  presented.  Operating  results  for the
interim  period are not  necessarily  indicative of results that may be expected
for the year ending December 31, 2001. These financial statements should be read
in conjunction  with the financial  statements and notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 2000.

NOTE 2 -- EARNINGS PER SHARE:

     The  reconciliation  of the  numerators and  denominators  of the basic and
diluted EPS from continuing operations  computations for the three and six-month
periods ended June 30, 2001 and 2000 is as follows  (000's  omitted,  except for
per share amounts):

<TABLE>

<CAPTION>
                                                                        For the               For the
                                                                  three-month period     six-month period
                                                                    ended June 30,         ended June 30,
                                                                  ------------------    --------------------
                                                                    2001       2000        2001       2000
                                                                  --------   -------    ---------  ---------
                                                                     (unaudited)            (unaudited)
Numerator
---------
<S>                                                               <C>        <C>         <C>         <C>
Net Income .....................................................  $   406    $   368     $   765     $   658
Less: Preferred Stock dividends paid ...........................      (33)       (33)        (66)        (66)
                                                                  -------    -------     -------     -------
Net income available to common stockholders ....................  $   373    $   335     $   699     $   592
                                                                  =======    =======     =======     =======

Denominator
-----------
Weighted average shares basic ..................................    2,993      4,163       3,109       4,270
Effect of dilutive options and warrants ........................      112         63          41          64
                                                                  -------    -------     -------     -------
Weighted average shares and dilutive potential
    common shares ..............................................    3,105      4,226       3,150       4,334
                                                                  =======    =======     =======     =======

Basic EPS ......................................................  $  0.12    $  0.08     $  0.22     $  0.14
Diluted EPS ....................................................  $  0.12    $  0.08     $  0.22     $  0.14
</TABLE>


     For the three and six-month  period ended June 30, 2001,  the effect of the
assumed exercise of options to purchase approximately 247,000 and 473,000 shares
of Common Stock,  respectively,  at exercise  prices ranging from $4.50 to $5.38
and from $4.00 to $5.38, respectively,  per share were excluded in computing the
diluted per share amount because the exercise prices of the options were greater
than the average market price of the shares of Common Stock,  therefore  causing
these options to be antidilutive.  For the three and six-month period ended June
30,  2001,  the  effect  of  the  assumed   exercise  of  warrants  to  purchase
approximately  25,000  and  62,000  shares of  Common  Stock,  respectively,  at
exercise  prices  ranging from $5.13 to $7.24 and $4.12 to $7.24,  respectively,
per share were  excluded in computing  the diluted per share amount  because the
exercise  prices of the warrants  were greater than the average  market price of
the shares of Common Stock, therefore causing these warrants to be antidilutive.

                                      -6-
<PAGE>


                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)

     For the three and six-month  periods ended June 30, 2000, the effect of the
assumed exercise of options to purchase  approximately  550,000 shares of Common
Stock at exercise  prices ranging from $3.19 to $5.00 per share were excluded in
computing  the  diluted per share  amount  because  the  exercise  prices of the
options  were  greater  than the  average  market  price of the shares of Common
Stock,  therefore,  causing these options to be antidilutive.  For the three and
six-month  periods  ended June 30, 2000,  the effect of the assumed  exercise of
warrants to purchase  approximately  103,000  shares of Common Stock at exercise
prices  ranging  from $4.12 to $8.54 per share were  excluded in  computing  the
diluted  per share  amount  because the  exercise  prices of the  warrants  were
greater than the average market price of the shares of Common Stock,  therefore,
causing these warrants to be antidilutive.

     For the three  month and six month  periods  ended June 30,  2001 and 2000,
approximately  133,000  shares of Common  Stock from the assumed  conversion  of
Preferred  Stock were excluded in computing the diluted per share amount as they
were antidilutive.

NOTE 3 -- SEGMENT INFORMATION:

     The Company is  principally  engaged in providing  products and services to
the fertility market. For disclosure  purposes,  the Company recognizes Business
Services  offered  to its  network  of  Reproductive  Science  Centers  and  its
pharmaceutical distribution operations as separate reporting segments as follows
(000's omitted):

<TABLE>
<CAPTION>
                                                                                     Business        Pharmaceutical
                                                                  Corporate          Services         Distribution      Consolidated
                                                                  ---------          --------         ------------      ------------

For the three months ended June 30, 2001
<S>                                                                <C>                <C>                <C>                <C>
     Revenues ...........................................          $   --             $ 14,685           $  3,602           $ 18,287
     Cost of Services ...................................              --               12,245              3,435             15,680
     Contribution .......................................              --                2,440                167              2,607
                                                                   --------           --------           --------           --------
     General and administrative expenses ................             1,880               --                 --                1,880
     Amortization of intangibles ........................                 1                222                  2                225
     Interest, net ......................................                42                 (6)                (3)                33
                                                                   --------           --------           --------           --------
     Income before income taxes .........................            (1,923)             2,224                168                469
     Depreciation expense included above ................               108                300               --                  408
     Capital expenditures ...............................               104                410               --                  514

For the six months ended June 30, 2001
     Revenues ...........................................          $   --             $ 27,715           $  7,063           $ 34,778
     Cost of Services ...................................              --               23,066              6,758             29,824
     Contribution .......................................              --                4,649                305              4,954
     Other costs ........................................             3,569               --                 --                3,569
     Amortization of intangibles ........................                 2                435                  4                441
     Interest, net ......................................                86                (17)                (4)                65
                                                                   --------           --------           --------           --------
     Income before income taxes .........................            (3,657)             4,231                305                879
     Depreciation expense included above ................               214                574               --                  788
     Capital expenditures ...............................               161              1,130               --                1,291

</TABLE>

                                      -7-
<PAGE>

<TABLE>

<CAPTION>
                                                                                       Business       Pharmaceutical
                                                                    Corporate          Services        Distribution     Consolidated
                                                                    ---------          --------        ------------     ------------

For the three months ended June 30, 2000
<S>                                                                  <C>                <C>               <C>                <C>
     Revenues ............................................           $  --              $11,524           $ 2,003            $13,527
     Cost of Services ....................................              --                9,500             1,948             11,448
                                                                     -------            -------           -------            -------
     Contribution ........................................              --                2,024                55              2,079

     General and administrative expenses .................             1,390               --                --                1,390
     Amortization of intangibles .........................                 1                211                 2                214
     Interest, net .......................................                71                  1                (4)                68
                                                                     -------            -------           -------            -------

     Income before income taxes ..........................            (1,462)             1,812                57                407

     Depreciation expense included above .................               118                345              --                  463
     Capital expenditures ................................                29                193              --                  222

For the six months ended June 30, 2000
     Revenues ............................................              --               23,262             3,873             27,135
     Cost of Services ....................................              --               19,333             3,753             23,086
                                                                     -------            -------           -------            -------
     Contribution ........................................              --                3,929               120              4,049

     Other costs .........................................             2,739               --                --                2,739
     Amortization of intangibles .........................                12                418                 4                434
     Interest, net .......................................               130                 10                (6)               134
                                                                     -------            -------           -------            -------

     Income before income taxes ..........................            (2,881)             3,501               122                742

     Depreciation expense included above .................               236                679              --                  915
     Capital expenditures ................................                51                537              --                  588
</TABLE>


NOTE 4 -- NEW ACCOUNTING PRONOUNCEMENTS:

     In July 2001, the Financial Accounting Standards Board issued Statements of
Financial  Accounting  Standards No. 141, Business  Combinations ("FAS 141") and
No. 142, Goodwill and Other Intangible  Assets ("FAS 142").  FAS141 requires all
business  combinations  initiated  after June 30, 2001 to be accounted for using
the  purchase  method.  Under  FAS 142,  goodwill  and  intangible  assets  with
indefinite  lives are no longer  amortized  but are  reviewed  annually (or more
frequently if impairment indicators arise) for impairment.  Separable intangible
assets  that  are not  deemed  to have  indefinite  lives  will  continue  to be
amortized over their useful lives (but with no maximum life).  The  amortization
provisions of FAS 142 apply to goodwill and  intangible  assets  acquired  after
June 30, 2001. With respect to goodwill and intangible  assets acquired prior to
July 1, 2001, the Company is required to adopt FAS 142 effective January 1, 2002
and is currently  evaluating  the effect that adoption of the  provisions of FAS
142 will have on its results of operations and financial position.

                                      -8-

<PAGE>



Item 2.  Management's Discussion and Analysis of Financial Condition
          and Results of Operations

     The following  discussion and analysis  should be read in conjunction  with
the  consolidated  financial  statements  and  notes  thereto  included  in this
quarterly  report and with the Company's Annual Report on Form 10-K for the year
ended December 31, 2000.

     IntegraMed  America,  Inc. (the "Company")  offers products and services to
patients,  providers,  payors and pharmaceutical  manufacturers in the fertility
industry. The IntegraMed Network is comprised of twenty-two fertility centers in
major  markets  across  the  United  States,   a   pharmaceutical   distribution
subsidiary,  a financing  subsidiary,  the Council of Physicians and Scientists,
and  a  leading  fertility  portal  (www.integramed.com).   Seventeen  of  these
fertility centers have access to the Company's  FertilityDirect Program. Five of
the fertility centers are designated as "Reproductive Science Centers(R)" and as
such, have access to the Company's  FertilityDirect Program in addition to being
provided with a full range of services including:  (i) administrative  services,
including  accounting and finance,  human resource functions,  and purchasing of
supplies and equipment;  (ii) access to capital; (iii) marketing and sales; (iv)
integrated  information  systems;  (v) assistance in  identifying  best clinical
practices; and (vi) laboratory services (collectively, "Business Services").

     The Company's strategy is to align information,  technology and finance for
the  benefit  of  fertility  patients,   providers,  payors  and  pharmaceutical
manufacturers.  The primary  elements of the  Company's  strategy  include:  (i)
selling  additional  FertilityDirect  contracts to leading  fertility centers in
major markets; (ii) selling Shared Risk Refund Treatment Packages to patients of
contracted fertility centers and managing the risk associated with the programs;
(iii) selling additional Reproductive Science Center Business Service contracts;
(iv) increasing revenues at Reproductive  Science Centers;  (v) increasing sales
of  pharmaceutical  products and  services;  (vi)  expanding  clinical  research
opportunities;  and (vii) establishing Internet-based access to patient-specific
information on treatment process and outcomes.

     In December  2000,  the Company's  agreement  with the medical center based
Reproductive  Science Center was terminated  early.  The Company  received $1.44
million in liquidated  damages pursuant to an early termination  agreement.  The
amount  received was recorded as deferred  revenue at December 31, 2000,  as the
Company  has  certain   transition   obligations   through  December  2001,  and
accordingly  is being  amortized  ratably into income in 2001. It is anticipated
that the cost of the transition obligations incurred to date, and those expected
to  be  incurred  during  the  remainder  of  the  transition  period,  will  be
immaterial.

     The  Company  is  under  pressure  to  reduce  the fees it  charges  to the
Reproductive  Science Centers for Business  Services and may be forced to reduce
such fees. Cost containment  measures which the Company may implement may not be
enough to offset these fee reductions.  In addition,  as the Company  implements
its  strategy to become a  marketing-oriented  in  addition  to a  service-based
company,  costs of implementation may be incurred prior to achieving the related
revenues.  As a result of these  issues,  near term income levels may be reduced
and the Company may not achieve the earnings level  experienced in the first two
quarters of 2001.

                                      -9-

<PAGE>


Results of Operations

     The following table shows the percentage of revenues represented by various
expense and other income items reflected in the Company's Consolidated Statement
of Operations.

<TABLE>
<CAPTION>
                                                                   For the                For the
                                                             three-month period      six-month period
                                                               ended June 30,         ended June 30,
                                                             -------------------     -----------------
                                                               2001       2000         2001      2000
                                                              ------     ------      -------   -------
                                                                (unaudited)            (unaudited)

<S>                                                           <C>        <C>         <C>        <C>
 Revenues, net............................................    100.0%     100.0%      100.0%     100.0%
 Cost of services incurred:
      Employee compensation and related expenses..........     40.7       39.7        39.2       38.6
      Direct materials....................................     21.6       19.8        22.4       19.0
      Occupancy costs.....................................      4.8        6.3         5.4        6.1
      Depreciation........................................      1.7        2.5         1.7        2.5
      Other expenses......................................     17.0       16.3        17.1       18.9
                                                              -----     ------       -----      -----
      Total cost of services incurred.....................     85.8       84.6        85.8       85.1
 Contribution.............................................     14.2       15.4        14.2        4.9
                                                              -----     ------       -----      -----
 General and administrative expenses......................     10.3       10.3        10.2       10.1
 Amortization of intangible assets........................      1.2        1.6         1.3        1.6
 Interest income..........................................     (0.2)      (0.3)       (0.3)      (0.3)
 Interest expense.........................................      0.4        0.8         0.5        0.8
                                                             ------     ------      ------     ------
      Total other expenses................................     11.7       12.4        11.7       12.2
 Income before income taxes...............................      2.5        3.0         2.5        2.7
 Provision for income taxes...............................      0.3        0.3         0.3        0.3
                                                             ------     ------      ------     ------
 Net income...............................................      2.2%       2.7%        2.2%       2.4%
                                                             ======     ======      ======     ======
</TABLE>


   Three Months Ended June 30, 2001 Compared to Three Months Ended June 30, 2000

     Revenues for the three  months  ended June 30, 2001 (the second  quarter of
2001) were  approximately  $18.3  million as  compared  to  approximately  $13.5
million  for the  three  months  ended  June 30,  2000,  an  increase  of 35.2%.
Approximately  66% of the  increase in revenues is  attributable  to same market
growth in reimbursed costs and business service fees in the Reproductive Science
Centers.  Approximately 34% of the increase in revenues is attributable to sales
increases in the Company's pharmaceutical distribution division.

     Total  costs of  services as a  percentage  of  revenues  were 85.8% in the
second  quarter  of  2001,  compared  to 84.6% in the  second  quarter  of 2000.
Employee compensation  increased as a percentage of revenues due to expansion of
services  provided and  increases  in patient  volume at the  Company's  Network
locations. Direct materials increased as a percentage of revenues, primarily due
to the  cost of  products  sold  at the  pharmaceutical  distribution  division.
Depreciation expense decreased as a percentage of revenues as the existing asset
base is  sufficient  to service  the  growing  patient  volume.  Other  expenses
increased as a percentage of revenues due to higher  support  costs,  and higher
volume generated  administrative  costs related to the Company's  pharmaceutical
distribution division.

     Contribution was  approximately  $2.6 million in the second quarter of 2001
as  compared  to $2.1  million in the second  quarter of 2000,  an  increase  of
approximately  25.4%.  This increase is the result of (i)  improving  margins at
various Reproductive Science Centers, a result of economies of scale attained by
increased  volume,  and (ii) improving volume and margins in the  pharmaceutical
distribution division.

                                      -10-
<PAGE>

     General and  administrative  expenses  for the second  quarter of 2001 were
approximately  $1.9  million as compared to  approximately  $1.4  million in the
second  quarter of 2000,  an increase of 35.3%.  The increase was largely due to
increases  in  staffing  and  compensation  attributable  to  implementation  of
initiatives  related to the Company's  internet marketing  strategy,  as well as
higher information systems support costs.

     Amortization  of  intangible  assets was $225,000 in the second  quarter of
2001 as compared to $214,000 in the second  quarter of 2000, a increase of 5.1%.
This increase was  attributable to the purchase of additional  business  service
rights to  physician  practices  affiliated  with one of the  Company's  Network
locations.

     Interest  income for the second  quarter of 2001  increased to $44,000 from
$35,000 for the second quarter of 2000,  due to higher  available cash balances.
Interest  expense  for the second  quarter  of 2001  decreased  to $77,000  from
$103,000 in the second quarter of 2000, due to scheduled payments of debt on the
Company's line of credit.

     The  provision  for income  taxes  primarily  related to state  taxes.  The
provision  for income taxes  increased to $63,000 in the second  quarter of 2001
from $39,000 in the second  quarter of 2000 in line with  increased  earnings at
network site locations.

     Net  income was  $406,000  in the second  quarter  of 2001 as  compared  to
$368,000 in the second  quarter of 2000, an increase of 10.3%.  The increase was
primarily due to (i) improving  margins at the Reproductive  Science Centers and
the  Company's  pharmaceutical  distribution  division,  offset by  increases in
general and  administrative  expenses at the  Company's  headquarters,  and (ii)
decreases in interest expense related to the pay-down of debt.

   Six Months Ended June 30, 2001 Compared to Six Months Ended June 30, 2000

     Revenues  for the six months ended June 30, 2001 were  approximately  $34.8
million as compared to approximately $27.1 million for the six months ended June
30, 2000, an increase of 28.2%. Approximately 58% of the increase in revenues is
attributable to same market growth in reimbursed costs and business service fees
in the  Reproductive  Science  Centers.  Approximately  42% of the  increase  in
revenues is  attributable  to sales  increases in the  Company's  pharmaceutical
distribution division.

     Total  costs of  services as a  percentage  of revenues  were 85.8% for the
first six months of 2001, compared to 85.1% during the first six months of 2000.
Direct materials increased as a percentage of revenues, due to increased patient
volumes  at the  network  sites  and  higher  volume  of  products  sold  at the
pharmaceutical  distribution  division.  Depreciation  expense  decreased  as  a
percentage  of revenues as the existing  asset base is sufficient to service the
growing patient volume. Other expenses decreased as a percentage of revenue, due
to  decreases  in  contract  termination  costs and  non-payroll  marketing  and
consulting expenses.

     Contribution  was  approximately  $5.0  million for the first six months of
2001 as compared to $4.0  million for the first six months of 2000,  an increase
of  approximately  22.4%.  This  increase is the result of (i)  increased  asset
leverage as a result of patient volume increases at various Reproductive Science
Centers, (ii) improving margins in the pharmaceutical distribution division, the
result of increased  sales to patients at the various  Network Sites,  and (iii)
elimination of operating  losses at the Kansas City based  Reproductive  Science
Center which was closed during the first quarter of 2000.

     General and  administrative  expenses for the first six months of 2001 were
approximately  $3.6  million as compared to  approximately  $2.7 million for the
first six months of 2000, an increase of 30.3%.  The increase was largely due to
increases  in  staffing  and  compensation  attributable  to  implementation  of
initiatives  related  to  the  Company's  internet  marketing  strategy.   As  a
percentage  of  revenues,  general  and  administrative  expenses  increased  to
approximately  10.2% in the first six  months of 2001 from  approximately  10.1%
during the same period in 2000.

     Amortization of intangible  assets was $441,000 during the first six months
of 2001 as  compared to  $434,000  for the same  period in 2000,  an increase of
1.6%. This increase was  attributable  to the purchase of additional  management
rights to  physician  practices  affiliated  with two of the  Company's  Network
locations.

                                      -11-
<PAGE>

     Interest  income for the first six months of 2001 increased to $98,000 from
$85,000 for the first six months of 2000, due to higher available cash balances.
Interest  expense for the first six months of 2001  decreased  to $163,000  from
$219,000 for the first six months of 2000, due to scheduled  payments of debt on
the Company's line of credit.

     The  provision  for income  taxes  primarily  related to state  taxes.  The
provision for income taxes  increased to $114,000 during the first six months of
2001 from $84,000 in the same period in 2000 in line with increased  earnings at
network site locations.

     Net income was  $765,000  for the first six months of 2001 as  compared  to
$658,000  for the same period in 2000,  an increase of 16.3%.  The  increase was
primarily due to (i) improving  margins at the Reproductive  Science Centers and
the  Company's  pharmaceutical  distribution  division,  offset by  increases in
general  and  administrative  expenses  at  the  Company's  headquarters,   (ii)
decreases in interest  expense  related to the  pay-down of debt,  and (iii) the
elimination of operational  expenses related to the wind down of the Kansas City
Reproductive Science Center operations.

Liquidity and Capital Resources

     Historically,  the Company has financed its  operations  primarily  through
operating cash flow, sales of equity securities and bank financings.  As of June
30, 2001, the Company had working capital of approximately $2.5 million and cash
and cash equivalents of approximately $5.1 million,  compared to working capital
of  approximately  $4.9 million and cash and cash equivalents of $5.3 million at
December  31,  2000.  The net  decrease in working  capital at June 30, 2001 was
principally due to (i) the repurchase of 880,072 shares of the Company's  Common
Stock for an aggregate  purchase  price of $2.0  million,  repayments of debt of
$0.5  million  and  acquisition  of fixed  assets  of $1.3  million  and (ii) an
increase in amounts due to physician  practices for income earned at the Network
Sites of $1.2 million and an increase in patient deposits of $1.6 million.

     The  Company  expects  its cash flows from  operating  activities  and bank
financing  capacity to be  sufficient  to fund its needs for asset  acquisition,
debt repayments, the Common Stock repurchase program and new service initiatives
for the next year.

Forward Looking Statements

     This Form 10-Q and discussions and/or announcements made by or on behalf of
the Company, contain certain forward-looking  statements regarding events and/or
anticipated  results  within the  meaning of the safe harbor  provisions  of the
Private  Securities  Litigation  Reform  Act of 1995,  the  attainment  of which
involve  various  risks and  uncertainties.  Forward-looking  statements  may be
identified by the use of forward-looking terminology such as, may, will, expect,
believe, estimate,  anticipate,  continue, or similar terms, variations of those
terms or the negative of those terms.  The Company's  actual  results may differ
materially from those described in these  forward-looking  statements due to the
following factors:  the Company's ability to acquire additional business service
agreements,  including the  Company's  ability to raise  additional  debt and/or
equity  capital to  finance  future  growth,  the loss of  significant  business
service agreement(s),  the profitability or lack thereof at Reproductive Science
Centers  serviced by the Company,  increases in overhead due to  expansion,  the
exclusion of infertility  and ART services from insurance  coverage,  government
laws and regulations regarding health care, changes in managed care contracting,
the timely development of and acceptance of new infertility,  ART and/or genetic
technologies and techniques.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

     Not applicable.

                                      -12-
<PAGE>



Part II -         OTHER INFORMATION

     Item 1.      Legal Proceedings.
                     In July 1999, an action was filed in Middlesex Superior
                  Court in Massachusetts, against the Company, the Reproductive
                  Science Center of Boston (the "Center"), an independent
                  genetic testing laboratory, and certain of their respective
                  employees. The Complaint was served on the Company in March
                  2000. The action, filed by two former patients of the Center,
                  arose out of Plaintiffs' participation during 1966 in an
                  experimental program of pre-implantation genetic testing. The
                  Plaintiffs had alleged professional negligence and breach of
                  contract/warranties resulting in the birth of their child who
                  suffers with cystic fibrosis. Plaintiffs sought damages of an
                  undisclosed amount. The Company's insurance carrier appointed
                  Massachusetts counsel to represent the Company in the matter
                  that was settled in July 2001 with a payment by the carrier to
                  Plaintiffs without any impact to the Company's financial
                  position, results of operations or cash flows.

     Item 2.      Changes in Securities.
                     None.

     Item 3.      Defaults Upon Senior Securities.
                     None.

     Item 4.      Submission of Matters to Vote of Security Holders.
                     At an annual shareholders' meeting held on May 22, 2001,
                     the following matter was approved:

                     1)  election of six directors

                     The respective vote tabulations are detailed below:

                                                                       Withhold
                     Proposal 1 - Directors             For           Authority
                     ----------------------             ---           ---------
                     Gerardo Canet                   2,438,131          7,545
                     Michael J. Levy, M.D.           2,438,131          7,545
                     Sarason D. Liebler              2,438,131          7,545
                     Aaron S. Lifchez, M.D.          2,438,131          7,545
                     Lawrence Stuesser               2,438,131          7,545
                     Elizabeth E. Tallett            2,438,131          7,545

     Item 5.      Other Information.
                     None.

     Item 6.      Exhibits and Reports on Form 8-K.
                     See Index to Exhibits on Page 15.

                                      -13-
<PAGE>


                                   SIGNATURES



         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                              INTEGRAMED AMERICA, INC.
                                              (Registrant)




Date:    August 14, 2001                    By:  /s/ John W. Hlywak, Jr.
                                                 --------------------------
                                                 John W. Hlywak, Jr.
                                                 Senior Vice President and
                                                 Chief Financial Officer
                                                 (Principal Financial and
                                                 Accounting Officer)

                                      -15-
<PAGE>



Exhibit
Number                                  Exhibit
-------                                 -------

10.88(d)  --  Amendment to Management  Agreement  between  IntegraMed  America,
              Inc. and MPD Medical Associates (MA) P.C. dated May 25, 2001.

99.4      --  Registrant's Press Release dated May 2, 2001 (1)

99.5      --  Registrant's Press Release dated August 1, 2001 (2)
--------------------------------------------------------

(1)   Filed as exhibit with identical exhibit number to Registrant's  Report on
      Form 8-K dated May 2, 2001

(2)   Filed as exhibit with identical exhibit number to Registrant's  Report on
      Form 8-K dated August 1, 2001


                                      -15-